The company, already scaling across Europe, plans to accelerate the deployment of its medication reconciliation platform in the United States
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Innovative TIMScore for dda-PASEF and dia-PASEF libraries, combined with TIMS DIA-NN identifies 9000 protein groups from 200 ng K562 lysate in just 35 min gradient
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
Subscribe To Our Newsletter & Stay Updated
